Enantioselective metabolism of primaquine by human CYP2D6

BACKGROUND: Primaquine, currently the only approved drug for the treatment and radical cure of Plasmodium vivax malaria, is still used as a racemic mixture. Clinical use of primaquine has been limited due to haemolytic toxicity in individuals with genetic deficiency in glucose-6-phosphate dehydrogen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Malar J
Main Authors: Fasinu, Pius S, Tekwani, Babu L, Nanayakkara, NP Dhammika, Avula, Bharathi, Herath, HMT Bandara, Wang, Yan-Hong, Adelli, Vijender R, Elsohly, Mahmoud A, Khan, Shabana I, Khan, Ikhlas A, Pybus, Brandon S, Marcsisin, Sean R, Reichard, Gregory A, McChesney, James D, Walker, Larry A
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4301821/
https://ncbi.nlm.nih.gov/pubmed/25518709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-13-507
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki